- $33.72m
- -$7.85m
- $8.98m
Brief: InspireMD Reports Publication of 12-Month Results of CGuard EPS SIBERIA Trial
Brief: InspireMD Inc Receives Reimbursement Approval For CGUARD Embolic Prevention System From The French National Authority For Health
Brief: InspireMD Announces Strong Second Quarter 2021 Financial Results
InspireMD Inc reports results for the quarter ended in June - Earnings Summary
InspireMD Inc expected to post a loss of 63 cents a share - Earnings Preview
InspireMD Inc expected to post a loss of 63 cents a share - Earnings Preview
InspireMD: Rises on positive data from carotid artery disease study